In vitro effect of new formulations of amphotericin B on amastigote and promastigote forms of Leishmania infantum

International Journal of Antimicrobial Agents

Volumn 30, Issue 4, 2007, Pages 325-329

  Ordóñez Gutiérrez, Lara ^a   Espada Fernández, Raquel ^b   Dea Ayuela, María Auxiliadora ^b   Torrado, Juan José ^b   Bolás Fernandez, Francisco ^b   Alunda, José María ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Albumin; Amastigote; Amphotericin B; In vitro; Leishmania infantum; Microencapsulation

Indexed keywords

ALBUMIN; AMPHOTERICIN B; ANTILEISHMANIAL AGENT; DIMER; MICROSPHERE; MONOMER; POLYGLACTIN; POLYMER; RESOMER;

AMASTIGOTE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; ENCAPSULATION; LEISHMANIA INFANTUM; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE;

ALBUMINS; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; GLYCOLATES; LEISHMANIA INFANTUM; LIFE CYCLE STAGES; MACROPHAGES; MICE; MICROSPHERES; PARASITIC SENSITIVITY TESTS;

EID: 34548424875     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.05.013     Document Type: Article

References (33)

1. Alvar J., Cañavate C., Gutiérrez-Solar B., et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10 (1997) 298-319
2. Badaro R., Carvalho E.M., Rocha H., Queiroz A.C., and Jones T.C. Leishmania donovani: an opportunistic microbe associated with progressive disease in three immunocompromised patients. Lancet 1 (1986) 647-649
3. Alvar J., Cañavate C., Molina R., Moreno J., and Nieto J. Canine leishmaniasis. Adv Parasitol 57 (2004) 1-88
4. Abranches P., Silva-Pereira M.C., Conceiçao-Silva F.M., Santos-Gomes G.M., and Janz J.G. Canine leishmaniasis: pathological and ecological factors influencing transmission of infection. J Parasitol 77 (1991) 557-561
5. Morillas F., Sánchez-Rabasco F., Ocaña J., et al. Leishmaniosis in the focus of the Axarquia region, Malaga province, southern Spain: a survey of the human, dog, and vector. Parasitol Res 82 (1996) 569-570
6. Iniesta L., Fernández-Barredo S., Bulle B., et al. Diagnostic techniques to detect cryptic leishmaniasis in dogs. Clin Diagn Lab Immunol 9 (2002) 1137-1141
7. Santos W.R., Aguiar I.A., Paraguai de Souza E., de Lima V.M., Palatnik M., and Palatnik-de-Sousa C.B. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 21 (2003) 4668-4676
8. Berman J.D., Badaro R., Thakur C.P., et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 76 (1998) 25-32
9. Filippin F.B., and Souza L.C. Eficiência terapêutica das formulaçoes lipídicas de anfotericina B. Braz J Pharm Sci 42 (2006) 167-194
10. Croft S.L., Sundar S., and Fairlamb A.H. Drug resistance in leishmaniasis. Clin Microbiol Rev 19 (2006) 111-126
11. Berman J.D. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24 (1997) 684-703
12. Brajtburg J., and Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 9 (1996) 512-531
13. Yardley V., and Croft S.L. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 41 (1997) 752-756
14. Kuti J.L., Kotapati S., Williams P., Capitano B., Nightingale C.H., and Nicolau D.P. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 22 (2004) 301-310
15. D'Souza M.J., Oettinger C.W., Shah A., Tipping P.G., Huang X.R., and Milton G.V. Macrophage depletion by albumin microencapsulated clodronate: attenuation of cytokine release in macrophage-dependent glomerulonephritis. Drug Dev Ind Pharm 25 (1999) 591-596
16. Sánchez-Brunete J.A., Dea M.A., Rama S., et al. Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B. J Drug Target 13 (2005) 225-233
17. Mikus J., and Steverding D. A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol Int 48 (2000) 265-269
18. Méndez S., Nell M., and Alunda J.M. Leishmania infantum: infection of macrophages in vitro with promastigotes. Int J Parasitol 26 (1996) 619-622
19. Killick Kendrick R., and Rioux J.A. Intravectorial cycle of Leishmania in sandflies. Ann Parasitol Hum Comp 66 Suppl. 1 (1991) 71-74
20. Burchmore R.J., and Hart D.T. Glucose transport in amastigotes and promastigotes of Leishmania mexicana mexicana. Mol Biochem Parasitol 74 (1995) 77-86
21. Hart D.T., and Coombs G.H. Leishmania mexicana: energy metabolism of amastigotes and promastigotes. Exp Parasitol 54 (1982) 397-409
22. Berman J.D., and Wyler D.J. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infect Dis 142 (1980) 83-86
23. Baneth G., and Shaw S.E. Chemotherapy of canine leishmaniosis. Vet Parasitol 106 (2002) 315-324
24. Bolard J., Legrand P., Heitz F., and Cybulska B. One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium. Biochemistry 30 (1991) 5707-5715
25. Berman J.D.U. US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 28 (1999) 49-51
26. Lamothe J. Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniasis. J Small Anim Pract 142 (2001) 170-175
27. Moreno M.A., Frutos P., and Ballesteros M.P. Lyophilized lecithin based oil-water microemulsions as a new and low toxic delivery system for amphotericin B. Pharm Res 18 (2001) 344-351
28. Sanchez-Brunete J.A., Dea M.A., Rama S., et al. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 48 (2004) 3246-3252
29. Espuelas M.S., Legrand P., Campanero M.A., et al. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicrob Chemother 52 (2003) 419-427
30. Piñero J.E., Martínez S., del Castillo A., Portús M., and Valladares B. In vitro susceptibility of Leishmania infantum strains isolated from Spanish HIV-positive patients to Abelcet and Fungizone. J Antimicrob Chemother 50 (2002) 304-306
31. Larabi M., Yardley V., Loiseau P.M., et al. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother 47 (2003) 3774-3779
32. Lewis R.E., and Wiederhold N.P. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?. Clin Infect Dis 37 (2003) 871-872
33. Chéron M., Petit C., Bolard J., and Gaboriau F. Heat-induced reformulation of amphotericin B-deoxycholate favours drug uptake by the macrophage-like cell line J774. J Antimicrob Chemother 52 (2003) 904-910